Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abbott's (ABT) Eterna SCS technology shows 23% more pain reduction compared with traditional waveform technology approaches.

Abbott's (ABT) Eterna SCS System Receives FDA's Approval

The U.S. Food and Drug Administration (FDA) approved Abbott's Eterna™ spinal cord stimulation (SCS) system for the treatment of chronic pain This neuromodulation device provides an optimized experience with the ability to wirelessly charge as few as five times per year, the lowest recharge burden compared to other rechargeable SCS systems §1,2,3 ABBOTT PARK, Ill., Dec. 19, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) approval of the company's Eterna™ spinal cord stimulation (SCS) system – the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain.

Abbott Launches the World's Smallest Implantable, Rechargeable Spinal Cord Stimulation System for Chronic Pain

Medical Properties Trust

Rising interest rates don't affect all passive income stocks equally.

1 Passive Income Stock to Buy Today, and 1 to Avoid for Now

Teladoc

These stocks look cheap -- especially considering their long-term potential.

2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year

Johnson & Johnson

These companies will work hard to grow your base of passive income.

Want $250 in Passive Income? Buy These 2 Dividend Kings and Wait

Target

These stocks will bring you income -- no matter what the market is doing.

2 Top Dividend Stocks to Buy Hand Over Fist Before 2023

Bullish momentum behind the big pharmaceutical company was aided by a glowing new analyst note.

Why Abbott Laboratories Topped the Market on Tuesday

Concussion Awareness Now is comprised of nearly 20 advocacy groups focused on brain injury and will work to raise awareness about the importance of diagnosis and treatment for concussions The vast majority of concussions happen in everyday accidents, and over half of people who suspect they have a concussion never get it checked Rebel Wilson sustained a concussion while on set producing and acting in a movie and is sharing her personal story to help raise awareness ABBOTT PARK, Ill., and WASHINGTON , Dec. 13, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) and the Brain Injury Association of America announced today they have cofounded a coalition of nearly 20 advocacy groups, and are teaming up with acclaimed actress, comedian, writer and producer Rebel Wilson to raise awareness of the seriousness of concussions.

Abbott and the Brain Injury Association of America launch Concussion Awareness Now coalition; team up with Rebel Wilson to raise awareness on seriousness of concussions

Johnson & Johnson and Abbott Laboratories are two Dividend Kings the analysts are buying, one stock is ready to rebound and the other to lead the market.

Two Blue Chip Health Companies The Institutions Are Buying

Following several years of steady growth, Abbott Laboratories ( ABT , Financial) reported disappointing results for the third quarter of 2022, causing investors to worry that further declines could be in store for the stock. Medical device sales were down sharply, adding to already-negative investor sentiment from an infant formula recall and production halt earlier this year due to an FDA inspection that found Cronobacter sakazakii bacteria, which can be deadly to infants, in several areas of the company's Sturgis, Michigan facility.

Abbott's 8% Dividend Hike Defies Disappointing Results

Abbott Laboratories ABT, +1.13% said Friday morning that it would be raising its dividend to 51 cents a share. The increase amounts to a 8.5% bump relative to the company's prior quarterly dividend of 47 cents a share.

Abbott Labs boosts dividend by more than 8%

Dividend increased by 8.5% Reflects Abbott's longstanding commitment to sustainable growth and shareholder returns ABBOTT PARK, Ill., Dec. 9, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 51 cents per share, an increase of 8.5%.

Abbott Increases Quarterly Dividend, Marking 51 Consecutive Years of Dividend Growth

Hormel Foods

Don't let these income stocks pass you by.

2 Supercharged Dividend Stocks to Buy in a Bear Market

Exxon Mobil

You can count on these dividend stocks to continue raising their payouts for years to come.

2 Dividend Aristocrats to Buy for 2023

Disney

These top stocks look like a deal right now.

Got $500? Where to Invest It Before 2023

San Diego, California--(Newsfile Corp. - November 29, 2022) - The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Abbott Laboratories (NYSE: ABT).Investors who purchased Abbott Laboratories (NYSE: ABT) shares prior to February 2021 and continue to hold any of their NYSE: ABT shares have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

NOTICE For Investors In ABT: Lawsuit against Abbott Laboratories announced by Shareholders Foundation

Intuitive Surgical

We believe Intuitive Surgical stock is currently a better pick than Abbott stock, given its better prospects. Although Abbott is trading at a comparatively lower valuation of 4.1x trailing revenues vs. 15.2x for Intuitive Surgical, this gap in the valuation is justified mainly given the latter's superior revenue growth and lower financial risk, as discussed below.

This Robotic Surgical Company Is Likely To Offer Better Returns Over Abbott Stock

Prologis

Some of the world's most successful investors made big bets on these dividend payers recently.

2 Unbeatable Dividend Stocks Billionaires Keep Buying in a Bear Market

Abbott is a market leader in medical device businesses such as vascular care and diabetes care. It also leads in the in-vitro diagnostic market. The likely decline of COVID testing heavily impacted the share price.

Abbott Laboratories: Good Execution And Attractive Valuation

Cardinal Health

Check out these three dividend aristocrats in the stock market this week.

Good Stocks To Invest In Now? 3 Dividend Aristocrats Stocks For Your List

AbbVie

These stocks offer you a gift: recurrent income just for owning them.

Want Passive Income in 2023? Buy These Dividend Kings

Accenture Plc

Microsoft

UnitedHealth Group

Inflation cooled more than expected recently. It could be the first sign of a different rate environment and a bullish stock market. These four stocks should profit either way due to their strong growth, profitable cash flows, and shareholder returns.

4 Growth Stocks To Buy As Inflation Cools

The stock of Abbott Labs is down 18%+ over the past 12 months and has significantly underperformed the broad healthcare sector. This is likely not what investors expected - typically a healthcare stock like Abbott would outperform during an inflationary bear market.

Abbott Laboratories: Prepare For A Tough 2023

Abbott (ABT) reported earnings 30 days ago. What's next for the stock?

Abbott (ABT) Up 7.7% Since Last Earnings Report: Can It Continue?

Investors continue to be optimistic about Abbott (ABT) owing to the strength in its Diabetes business.

News for Abbott Labs Stock (ABT)